BioInvent International AB (BIX0) Stock Price & Analysis
BIX0 Stock Chart & Stats
- Day’s Range
- EUR 0.53 - EUR 0.82
- 52-Week Range
- EUR 0.53 - EUR 3.21
- Previous Close
- EUR 0.82
- Volume
- 0
- Average Volume (3M)
- 76
- Market Cap
- EUR 32.45M
- Enterprise Value
- EUR 1.30B
- Total Cash (Recent Filing)
- EUR 224.56M
- Total Debt (Recent Filing)
- EUR 19.33M
- Price to Earnings (P/E)
- ―
- Beta
- 0.30
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Validation
BI-1808 has produced encouraging efficacy signals in heavily pretreated ovarian cancer, including responses and durable disease control. These data support continued development, strengthen BioInvent’s scientific credibility, and could improve partnering prospects if results are replicated in randomized studies.
Regulatory Support
FDA Fast Track designations recognize programs addressing serious diseases with high unmet need and can facilitate closer regulatory interaction during development. While not approval, this support improves the program’s development profile and may help BioInvent advance or partner the asset.
Conservative Leverage
Very low leverage gives BioInvent greater financial flexibility than a similarly loss-making biotech carrying substantial debt. Limited debt reduces interest and refinancing pressure, allowing available capital to remain focused on clinical programs, although equity erosion remains a concern.
Bears Say
Persistent Cash Burn
Sustained negative operating and free cash flow means BioInvent is consuming capital to fund development rather than self-financing operations. The apparent acceleration in burn increases the need for new funding or partnering and raises the risk that clinical priorities must be reduced.
Ongoing Unprofitable Operations
Deeply negative operating and net margins show that current revenue does not cover BioInvent’s research and development structure. Continued losses can erode equity and constrain investment capacity, making future progress increasingly dependent on successful financing or commercial milestones.
Funding And Partnering Dependence
BioInvent’s ability to sustain development depends on executing an incompletely covered rights issue and securing partners for important programs. This creates funding uncertainty beyond 2027 and could delay or narrow clinical work if capital or partnering support does not arrive.
BioInvent International AB News
BIX0 FAQ
What was BioInvent International AB’s price range in the past 12 months?
What is BioInvent International AB’s market cap?
When is BioInvent International AB’s upcoming earnings report date?
How were BioInvent International AB’s earnings last quarter?
Is BioInvent International AB overvalued?
Does BioInvent International AB pay dividends?
What is BioInvent International AB’s EPS estimate?
How many shares outstanding does BioInvent International AB have?
What happened to BioInvent International AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioInvent International AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Welschof
- Employees
- 109
- Website
- www.bioinvent.com
- Address
- The Gamma Building, Lund, SN, 223 70, SE
BioInvent International AB (BIX0) Earnings & Revenues
BIX0 Company Deck
BIX0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by encouraging BI-1808 response and progression-free survival data, FDA Fast Track designations, an ESMO Best Poster Award, planned randomized development, and a potentially extended cash runway through the end of 2027 if the covered portion of the rights issue is completed. The company nevertheless reported a substantial net loss, a sharp year-to-date sales decline due largely to the prior-year milestone comparison, planned workforce reductions, dependence on financing and partnering, and delays in BI-1206 data maturation.
View all DE:BIX0 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |